Boston Scientific reports $2.39B in Q3 sales — 5 insights

Boston Scientific increased its sales 7.7 percent to $2.39 billion for the third quarter of fiscal year 2018.

Here's what you should know:

1. The company's GAAP adjusted earnings were $432 million or $0.31 per share.

2. Boston Scientific Chairman CEO Mike Mahoney said in a statement, "Our strong results reflect our global team's focused efforts to execute our category leadership strategy and advance the standard of care. Through internal research and tuck-in acquisitions, we continue to bring meaningful innovations to market, enabling our customers to deliver life-changing care to millions of patients around the world."

3. Boston Scientific's endoscopy division increased sales from $403 million to $443 million.

4. The cardiovascular division led the quarter with $908 million in sales, up from $857 million.

5. Despite the strong quarter, Boston Scientific lowered its full-year guidance to between $9.79 billion and $9.83 billion. It was previously between $9.8 billion and $9.88 billion.

More articles on gastroenterology:
Enterome & Takeda to co-develop drug for Crohn's disease: 5 insights
Dr. Richard Blumberg earns spot in National Academy of Medicine — 3 insights
Central Maine Healthcare adds medical director in Dr. Sean McGarr — 4 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months